TMCnet News

AbVitro Appoints Samuel Broder, M.D., to its Board of Directors and Scientific Advisory Board [Global Data Point]
[November 05, 2014]

AbVitro Appoints Samuel Broder, M.D., to its Board of Directors and Scientific Advisory Board [Global Data Point]


(Global Data Point Via Acquire Media NewsEdge) "We are very fortunate to have attracted such an experienced clinician scientist with both academic and industry experience to our board," said Jeffrey M. Ostrove, Ph.D., AbVitro's chief executive officer. "Dr. Broder brings a wealth of knowledge in the immuno-oncology and immunologic disease space, supporting many of the areas that our immune sequencing technology is so powerful in." "AbVitro's unique, high-capacity single-cell immune sequencing technology is a brilliant advance. It represents a paradigm shift in identifying novel therapeutic and diagnostic targets, as well as completely human monoclonal antibodies related to cancer, autoimmune and infectious diseases, or any condition that features an immune component," stated Dr. Broder.



"We are tremendously pleased to welcome Dr. Sam Broder to the board of directors of AbVitro. Having someone of Dr. Broder's stature on the board not only validates our enthusiasm about the power and potential of this promising technology, but his deep expertise and experience will be invaluable to the company going forward," noted Casey Cunningham, M.D., a medical oncologist who is a member of AbVitro's board of directors and the chief scientific officer of Sante Ventures, the lead investor in AbVitro Inc.

Samuel Broder, M.D., is the former director of the National Cancer Institute (NCI), appointed by President Ronald Reagan. In this position, he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). He was also a co-developer of some of the first effective drugs for the treatment of AIDS (zidovudine, AZT; didanosine, ddI; and zalcitabine, ddC). After leaving the NCI, Dr. Broder became senior vice president for research and development at IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics as chief medical officer. He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award.


(c) 2014 GlobalData Provided by SyndiGate Media Inc. (Syndigate.info).

[ Back To TMCnet.com's Homepage ]